These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18927283)

  • 21. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.
    Dvorak K; Watts GS; Ramsey L; Holubec H; Payne CM; Bernstein C; Jenkins GJ; Sampliner RE; Prasad A; Garewal HS; Bernstein H
    Am J Gastroenterol; 2009 Feb; 104(2):302-9. PubMed ID: 19174784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
    Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
    Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
    Cronin J; McAdam E; Danikas A; Tselepis C; Griffiths P; Baxter J; Thomas L; Manson J; Jenkins G
    Am J Gastroenterol; 2011 Jan; 106(1):46-56. PubMed ID: 21157443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
    Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
    J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
    Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M
    Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
    Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
    Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
    Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
    van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
    Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation.
    Onwuegbusi BA; Aitchison A; Chin SF; Kranjac T; Mills I; Huang Y; Lao-Sirieix P; Caldas C; Fitzgerald RC
    Gut; 2006 Jun; 55(6):764-74. PubMed ID: 16368780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.
    Burjonrappa SC; Reddimasu S; Nawaz Z; Gao X; Sharma P; Loggie B
    Indian J Cancer; 2007; 44(1):1-5. PubMed ID: 17401217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus.
    Bian YS; Osterheld MC; Bosman FT; Fontolliet C; Benhattar J
    Am J Clin Pathol; 2000 Oct; 114(4):583-90. PubMed ID: 11026105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
    Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
    Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of MAL expression in precancerous lesions of the esophagus.
    Mimori K; Nishida K; Nakamura Y; Ieta K; Yoshikawa Y; Sasaki A; Ishii H; Alonso MA; Mori M
    Ann Surg Oncol; 2007 May; 14(5):1670-7. PubMed ID: 17151798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.